Jasper Therapeutics

JSPR

Market cap $25.6M

JSPR Hedge Fund Activity: Q1 2026 in Review

58 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2026, worth a combined $13.9M — down 61% from $35.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new JSPR positions and 9 closed out — a net gain of 4 holders — while 15 added to existing stakes and 13 trimmed.

The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $1.88M. The largest seller was Goldman Sachs, exiting entirely with an estimated $3.2M sold.

• 58 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2026, up from 55 in Q4 2025.
• Funds reported $13.9M of Jasper Therapeutics stock for Q1 2026, down 61% quarter-over-quarter.
• 13 funds opened new Jasper Therapeutics positions in Q1 2026 and 9 closed out, a net change of +4 holders.
• The largest Jasper Therapeutics buyer in Q1 2026 was Kingdon Capital Management, an estimated $1.88M added.
• The largest Jasper Therapeutics seller in Q1 2026 was Goldman Sachs, an estimated $3.2M sold.

Based on aggregated 13F filings for Q1 2026.